Sclerostin-erbB-3 interactions: Modulation of erbB-3 activity by sclerostin

Biochemical and Biophysical Research Communications

Volumn 402, Issue 2, 2010, Pages 421-424

  Craig, Theodore A ^a   Kumar, Rajiv ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Epidermal growth factor receptor; ErbB 3; Osteoblast; Sclerostin; Yeast two hybrid

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PROTEIN P42; PROTEIN P44; SCLEROSTIN;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

3T3 CELLS; AMINO ACID SEQUENCE; ANIMALS; BONE MORPHOGENETIC PROTEINS; CELL LINE; GENE LIBRARY; GENETIC MARKERS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; OSTEOBLASTS; RECEPTOR, ERBB-3; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 78149447051     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.048     Document Type: Article

References (28)

1. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., Shpektor D., Jonas M., Kovacevich B.R., Staehling-Hampton K., Appleby M., Brunkow M.E., Latham J.A. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003, 22:6267-6276.
2. Beighton P.H., Hanmersma H., Brunkow M.E. SOST-Related Sclerosing Bone Dysplasias. GeneReviews NCBI Bookshelf 2010.
3. Staehling-Hampton K., Proll S., Paeper B.W., Zhao L., Charmley P., Brown A., Gardner J.C., Galas D., Schatzman R.C., Beighton P., Papapoulos S., Hamersma H., Brunkow M.E. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 2002, 110:144-152.
4. Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., Skonier J.E., Zhao L., Sabo P.J., Fu Y., Alisch R.S., Gillett L., Colbert T., Tacconi P., Galas D., Hamersma H., Beighton P., Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 2001, 68:577-589.
5. Beighton P., Horan F., Hamersma H. A review of the osteopetroses. Postgrad. Med. J. 1977, 53:507-516.
6. Beighton P., Davidson J., Durr L., Hamersma H. Sclerosteosis - an autosomal recessive disorder. Clin. Genet. 1977, 11:1-7.
7. Beighton P., Durr L., Hamersma H. The clinical features of sclerosteosis, a review of the manifestations in 25 affected individuals. Ann. Intern. Med. 1976, 84:393-397.
8. Kusu N., Laurikkala J., Imanishi M., Usui H., Konishi M., Miyake A., Thesleff I., Itoh N. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J. Biol. Chem. 2003, 278:24113-24117.
9. Lowik C.W., van Bezooijen R.L. Wnt signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J. Musculoskelet. Neuronal Interact. 2006, 6:357.
10. van Bezooijen R.L., Svensson J.P., Eefting D., Visser A., van der Horst G., Karperien M., Quax P.H., Vrieling H., Papapoulos S.E., ten Dijke P., Lowik C.W. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J. Bone Miner. Res. 2007, 22:19-28.
11. Ellies D.L., Viviano B., McCarthy J., Rey J.P., Itasaki N., Saunders S., Krumlauf R. Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J. Bone Miner. Res. 2006, 21:1738-1749.
12. Winkler D.G., Sutherland M.S., Ojala E., Turcott E., Geoghegan J.C., Shpektor D., Skonier J.E., Yu C., Latham J.A. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J. Biol. Chem. 2005, 280:2498-2502.
13. Winkler D.G., Yu C., Geoghegan J.C., Ojala E.W., Skonier J.E., Shpektor D., Sutherland M.K., Latham J.A. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J. Biol. Chem. 2004, 279:36293-36298.
14. van Bezooijen R.L., Roelen B.A., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., Hamersma H., Papapoulos S.E., ten Dijke P., Lowik C.W. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 2004, 199:805-814.
15. Craig T.A., Bhattacharya R., Mukhopadhyay D., Kumar R. Sclerostin binds and regulates the activity of cysteine-rich protein 61. Biochem. Biophys. Res. Commun. 2010, 392:36-40.
16. Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., Struhl K. Current Protocols in Molecular Biology 2007, John Wiley and Sons.
17. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., Manning S.P., Swain P.M., Zhao S.C., Eustace B., Lappe M.M., Spitzer L., Zweier S., Braunschweiger K., Benchekroun Y., Hu X., Adair R., Chee L., FitzGerald M.G., Tulig C., Caruso A., Tzellas N., Bawa A., Franklin B., McGuire S., Nogues X., Gong G., Allen K.M., Anisowicz A., Morales A.J., Lomedico P.T., Recker S.M., Van Eerdewegh P., Recker R.R., Johnson M.L. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 2002, 70:11-19.
18. Little R.D., Recker R.R., Johnson M.L. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 2002, 347:943-944.
19. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., Wu D., Insogna K., Lifton R.P. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 2002, 346:1513-1521.
20. Centrella M., Canalis E. Isolation of EGF-dependent transforming growth factor (TGF beta-like) activity from culture medium conditioned by fetal rat calvariae. J. Bone Miner. Res. 1987, 2:29-36.
21. Coffin-Collins P.A., Hall B.K. Chondrogenesis of mandibular mesenchyme from the embryonic chick is inhibited by mandibular epithelium and by epidermal growth factor. Int. J. Dev. Biol. 1989, 33:297-311.
22. Dealy C.N., Scranton V., Cheng H.C. Roles of transforming growth factor-alpha and epidermal growth factor in chick limb development. Dev. Biol. 1998, 202:43-55.
23. Ishizeki K., Takahashi N., Nawa T. Formation of the sphenomandibular ligament by Meckel's cartilage in the mouse: possible involvement of epidermal growth factor as revealed by studies in vivo and in vitro. Cell Tissue Res. 2001, 304:67-80.
24. Miettinen P.J., Chin J.R., Shum L., Slavkin H.C., Shuler C.F., Derynck R., Werb Z. Epidermal growth factor receptor function is necessary for normal craniofacial development and palate closure. Nat. Genet. 1999, 22:69-73.
25. Nonaka K., Shum L., Takahashi I., Takahashi K., Ikura T., Dashner R., Nuckolls G.H., Slavkin H.C. Convergence of the BMP and EGF signaling pathways on Smad1 in the regulation of chondrogenesis. Int. J. Dev. Biol. 1999, 43:795-807.
26. Wong R.W. Transgenic and knock-out mice for deciphering the roles of EGFR ligands. Cell. Mol. Life Sci. 2003, 60:113-118.
27. Yoon Y.M., Oh C.D., Kim D.Y., Lee Y.S., Park J.W., Huh T.L., Kang S.S., Chun J.S. Epidermal growth factor negatively regulates chondrogenesis of mesenchymal cells by modulating the protein kinase C-alpha, Erk-1, and p38 MAPK signaling pathways. J. Biol. Chem. 2000, 275:12353-12359.
28. Chan S.Y., Wong R.W. Expression of epidermal growth factor in transgenic mice causes growth retardation. J. Biol. Chem. 2000, 275:38693-38698.